| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Over the last 12 months, insiders at Coya Therapeutics, Inc. have bought $0 and sold $0 worth of Coya Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Coya Therapeutics, Inc. have bought $55,007 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,800 shares for transaction amount of $12,934 was made by SNYDER DAVID S (Chief Financial Officer) on 2024‑11‑14.
| 2024-11-14 | SNYDER DAVID S | Chief Financial Officer | 1,800 0.0126% | $7.19 | $12,934 | -10.87% | ||
| 2024-11-13 | Swaminathan Arun | Chief Executive Officer | 5,000 0.0335% | $7.36 | $36,797 | -16.16% | ||
| 2024-11-11 | Swaminathan Arun | Chief Executive Officer | 5,000 0.0336% | $7.34 | $36,689 | -17.12% | ||
| 2024-11-11 | Grossman Fred | Chief Medical Officer | 2,710 0.0183% | $7.37 | $19,973 | -17.12% | ||
| 2023-08-22 | Lee Ann | director | 1,000 0.0104% | $3.62 | $3,620 | +94.16% | ||
| 2023-01-03 | Villalobos Anabella | director | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | Lee Ann | director | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | Hepner Adrian | Chief Medical Officer | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | GOLDSTEIN DOV A MD | director | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | Berman Howard | Chief Executive Officer | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | SNYDER DAVID S | Chief Financial Officer | 7,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | Garren Hideki | director | 2,000 – | $0 | $0 | -2.15% |
| Lee Ann | director | 17479 0.0745% | $83,200.04 | 2 | 0 | +94.16% |
| GOLDSTEIN DOV A MD | director | 10000 0.0426% | $47,600.00 | 1 | 0 | |
| Hepner Adrian | Chief Medical Officer | 10000 0.0426% | $47,600.00 | 1 | 0 | |
| Villalobos Anabella | director | 10000 0.0426% | $47,600.00 | 1 | 0 | |
| Berman Howard | Chief Executive Officer | 10000 0.0426% | $47,600.00 | 1 | 0 | |
| Swaminathan Arun | Chief Executive Officer | 10000 0.0426% | $47,600.00 | 2 | 0 | <0.0001% |
| SNYDER DAVID S | Chief Financial Officer | 8800 0.0375% | $41,888.00 | 2 | 0 | <0.0001% |
| Grossman Fred | Chief Medical Officer | 2710 0.0116% | $12,899.60 | 1 | 0 | <0.0001% |
| Garren Hideki | director | 2000 0.0085% | $9,520.00 | 1 | 0 |
$5,488,711 | 162 | 6.05% | $104.45M | |
$66,137,559 | 49 | 6.29% | $133.36M | |
$4,898,715 | 46 | 40.75% | $98.8M | |
$64,585,398 | 37 | -9.92% | $115.15M | |
$47,438,336 | 33 | -21.38% | $101.62M | |
$390,510 | 22 | 17.68% | $107.68M | |
$3,838,728 | 20 | -13.91% | $95.83M | |
$11,267,080 | 15 | -22.36% | $92.18M | |
$178,593,887 | 15 | -14.86% | $121.48M | |
$207,086 | 15 | 14.15% | $130.44M | |
$8,069,667 | 13 | -13.57% | $121.92M | |
$13,486,672 | 11 | 82.26% | $124.63M | |
$9,999,920 | 10 | -40.03% | $121.83M | |
$1,073,250 | 10 | 19.46% | $109.41M | |
$68,692,148 | 6 | -39.10% | $107.21M | |
Coya Therapeutics, Inc. (COYA) | $110,013 | 5 | 6.58% | $111.66M |
$149,778 | 4 | -45.16% | $138.16M | |
$4,999,995 | 1 | -67.50% | $110.51M | |
$2,590,000 | 1 | 37.38% | $144.98M |
| Increased Positions | 49 | +175% | 4M | +74.77% |
| Decreased Positions | 11 | -39.29% | 379,990 | -7.96% |
| New Positions | 29 | New | 3M | New |
| Sold Out Positions | 7 | Sold Out | 196,667 | Sold Out |
| Total Postitions | 66 | +135.71% | 8M | +66.81% |
| Dme Capital Management, Lp | $9,302.00 | 7.84% | 1.65M | 0 | 0% | 2025-09-30 |
| Aigh Capital Management Llc | $6,247.00 | 5.27% | 1.11M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $4,726.00 | 3.98% | 836,393 | -4,078 | -0.48% | 2025-09-30 |
| Cm Management, Llc | $1,695.00 | 1.43% | 300,000 | +100,000 | +50% | 2025-09-30 |
| Geode Capital Management, Llc | $886.00 | 0.75% | 156,845 | -242 | -0.15% | 2025-09-30 |
| Dauntless Investment Group, Llc | $865.00 | 0.73% | 153,021 | +101,932 | +199.52% | 2025-09-30 |
| Blackrock, Inc. | $395.00 | 0.33% | 69,958 | +1,702 | +2.49% | 2025-09-30 |
| Citadel Advisors Llc | $369.00 | 0.31% | 65,240 | +22,120 | +51.3% | 2025-09-30 |
| State Street Corp | $272.00 | 0.23% | 48,100 | 0 | 0% | 2025-09-30 |
| Marshall Wace, Llp | $236.00 | 0.2% | 41,825 | +41,825 | New | 2025-09-30 |